InMed Pharmaceuticals's EBIT per Share for the
three
months ended in Dec. 2024 was $-3.14.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-13.89.
During the past 3 years, the average EBIT per Share Growth Rate was 69.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 54.60% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 21.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for InMed Pharmaceuticals's EBIT per Share or its related term are showing as below:
INM'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -169.4 Med: -3.9 Max: 69.7
Current: 69.7
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of InMed Pharmaceuticals was 69.70% per year. The lowest was -169.40% per year. And the median was -3.90% per year.
INM's 3-Year EBIT Growth Rate is ranked better than 95.51% of 824
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs INM: 69.70
InMed Pharmaceuticals EBIT per Share Historical Data
The historical data trend for InMed Pharmaceuticals's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.89
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InMed Pharmaceuticals (NAS:INM) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
InMed Pharmaceuticals EBIT per Share Related Terms
Thank you for viewing the detailed overview of InMed Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INM has been successfully added to your 